Navigation Links
Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
Date:12/20/2011

CAMBRIDGE, England, December 21, 2011 /PRNewswire/ --

Arecor Limited has entered into a collaboration agreement with Eli Lilly and Company to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs.  Under this agreement, Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly.  In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas.  

Tom Saylor, CEO of Arecor, stated, "The next generation of protein and peptide therapeutics present significant formulation challenges. Arecor's stabilization tools may enable new products and presentations, which would otherwise not be possible, without additional processing or changes to standard manufacturing practices.  Lilly's strong support of innovation and emerging technologies offers Arecor the potential to apply Arecor's broad-ranging expertise in biomolecule stabilization to a leader in pharmaceutical application of the next generation of biologics."

Arecor is a pioneer in the stabilization of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into interactions between proteins and their immediate environment. Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products. Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation. As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.

Contact:

Tom Saylor, CEO
tsaylor@arecor.com
Arecor Limited
2 Cambridge Science Park
Cambridge, UK
http://www.arecor.com


'/>"/>
SOURCE Arecor
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Announces the Launch of its Analgesic and Diabetic Oral Fuse Delivery (OFD) Research Project Platforms
2. Enlight Biosciences Forms New Partnerships with AstraZeneca and Novo Nordisk
3. Diablo Valley Oncology Performs Breast Intraoperative Radiation Procedure - First in the East Bay
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. ArjoHuntleigh Forms New Division to Enhance the Quality Home Medical Care
6. Digital ArtForms Debuts iMedic3D, a Radically Different Approach to Radiology, at RSNA ‘11, and Announces the Addition of Dr. Eliot Siegel and Dr. David Kim to Its Advisory Board Members
7. Awarepoint Corporation and MEDITECH Collaborate to Integrate Technology Platforms
8. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
9. ContinuumRx Forms Healthcare Joint Venture with Mississippi Baptist Health Systems
10. Stereotaxis Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms
11. Sanofi: Sales Growth of 6.9% Thanks to Genzyme Acquisition and Performance of Growth Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):